# RECEIVED

# JAN 2 8 2003

BOX PATENT

TECH CENTER 1600/2900 Attorney Docket No. 24390

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SHINITZKY et al.

Examiner: S. Turner

Serial No.: 09/647,457

Art Unit: 1647

Filed:

November 29, 2000

For:

ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON

A NEW PEPTIDE

### SEQUENCE LISTING SUBMISSION STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

This is in response to the Notice to Comply with Sequence Requirements which was mailed December 26, 2002, with a one-month period for response. A new Sequence Listing is due to be filed by January 26, 2003. Accordingly, this new Sequence Listing is timely filed within the period set for reply by the Examiner.

In connection with the Sequence Listing submitted herewith, the undersigned attorney hereby states that:

- 1) The submission, filed herewith in accordance with 37  ${\tt CFR}$ 1.821(g), does not include new matter; and
- 2) The content of the attached paper copy and the attached computer readable copy of the Sequence Listing are the same.

Date: January 26, 2003

NATH & ASSOCIATES PLLC

1030 15<sup>th</sup> Street NW, 6<sup>th</sup> Floor Washington, D.C. 20005

Tel: (202) 775-8383 Fax: (202) 775-8396

GMN:JBG/SMM\seq.state

Respectfully submitted, NATH & ASSOCIATES PLLC

Gary M. Nath Reg. No. 26,965

Joshua B. Goldberg Reg. No. 44,126

Customer No. 20529

	Miss !
JAN 2 h	NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING MUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES
	Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).
	The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other: Applicants amendment to claim i presents new peptide structures which clack compliance. Sequences are regimed to us present reach of the designated peptide structures including the generic Sequence.  Applicant Must Provide!
	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
	For questions regarding compliance to these requirements, please contact:
	For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 Patentin Software Program Support
	Technical Assistance703-287-0200 To Purchase Patentin Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY